Alliances
Evotec is now a more powerful player in the infectious disease sector following the signing of its three-month-old deal to integrate Sanofi’s anti-infectives unit, including the majority of Sanofi’s infectious disease research portfolio and initiatives into its organization.
Cytokinetics released data from its Phase II clinical trial of reldesemtiv in patients with spinal muscular atrophy (SMA).
AbbVie and the Keck Graduate Institute (KGI) School of Pharmacy have partnered to form the first AbbVie-KGI Biopharmaceutical Industry Fellowship.
Regenxbio snagged $100 million from Novartis under its license agreement with gene-therapy company AveXis, which the Swiss company acquired for $8.7 billion earlier this year.
Translate Bio, headquartered in Lexington, Massachusetts, and Paris-based Sanofi are teaming up to develop five vaccines.
Biogen signed an exclusive option deal with Tokyo-based TMS for TMS-007 and backup compounds.
Luye Pharma Group Ltd., announced today it is expanding its relationship with U.S. biotech firm Elpis Biopharmaceuticals Corp., to work on dual-target based therapies for cancer patients who fail to respond to current treatment.
BioMarin Pharmaceutical received $20 million in milestone payments from Pfizer after the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved its applications for talazoparib.
Genentech, a Roche company, and Microbiotica signed a multi-year strategic collaboration to discover, develop and commercialize biomarkers, targets and drugs for inflammatory bowel disease (IBD).
Hookipa Biotech and Gilead inked a research collaboration deal to develop and commercialize therapeutics for hepatitis B (HBV) and HIV.
PRESS RELEASES